These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 32117831)

  • 1. Kawasaki Disease in Children Older Than 10 Years: A Clinical Experience From Northwest India.
    Jindal AK; Pilania RK; Guleria S; Vignesh P; Suri D; Gupta A; Singhal M; Rawat A; Singh S
    Front Pediatr; 2020; 8():24. PubMed ID: 32117831
    [No Abstract]   [Full Text] [Related]  

  • 2. Kawasaki disease at British Columbia's Children's Hospital.
    Ebbeson RL; Riley MR; Potts JE; Human DG; Malleson PN
    Paediatr Child Health; 2004 Sep; 9(7):466-70. PubMed ID: 19657410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delayed intravenous immunoglobulin treatment increased the risk of coronary artery lesions in children with Kawasaki disease at different status.
    Qiu H; He Y; Rong X; Ren Y; Pan L; Chu M; Wu R; Shi H
    Postgrad Med; 2018 May; 130(4):442-447. PubMed ID: 29745742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
    Hsieh KS; Weng KP; Lin CC; Huang TC; Lee CL; Huang SM
    Pediatrics; 2004 Dec; 114(6):e689-93. PubMed ID: 15545617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infliximab is the new kid on the block in Kawasaki disease: a single-centre study over 8 years from North India.
    Singh S; Sharma D; Suri D; Gupta A; Rawat A; Rohit MK
    Clin Exp Rheumatol; 2016; 34(3 Suppl 97):S134-8. PubMed ID: 27086575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Risk of Recrudescent Fever in Children With Kawasaki Disease Treated With Intravenous Immunoglobulin and Low-Dose vs High-Dose Aspirin.
    Platt B; Belarski E; Manaloor J; Ofner S; Carroll AE; John CC; Wood JB
    JAMA Netw Open; 2020 Jan; 3(1):e1918565. PubMed ID: 31899532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
    Tse SM; Silverman ED; McCrindle BW; Yeung RS
    J Pediatr; 2002 Apr; 140(4):450-5. PubMed ID: 12006960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Timing of intravenous immunoglobulin treatment and risk of coronary artery abnormalities in children with Kawasaki disease.
    Bal AK; Prasad D; Umali Pamintuan MA; Mammen-Prasad E; Petrova A
    Pediatr Neonatol; 2014 Oct; 55(5):387-92. PubMed ID: 24636168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kawasaki disease in Turkish children: a single center experience with emphasis on intravenous immunoglobulin resistance and giant coronary aneurysms.
    Yılmazer MM; Özdemir R; Meşe T; Küçük M; Öner T; Devrim İ; Bayram N; Güven B; Tavlı V
    Turk J Pediatr; 2019; 61(5):648-656. PubMed ID: 32104995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corticosteroid Therapy Might be Associated with the Development of Coronary Aneurysm in Children with Kawasaki Disease.
    Zhao CN; Du ZD; Gao LL
    Chin Med J (Engl); 2016 Apr; 129(8):922-8. PubMed ID: 27064036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effective use of echocardiography in children with Kawasaki disease.
    Scott JS; Ettedgui JA; Neches WH
    Pediatrics; 1999 Nov; 104(5):e57. PubMed ID: 10545583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kawasaki disease: a comprehensive review of treatment options.
    Patel RM; Shulman ST
    J Clin Pharm Ther; 2015 Dec; 40(6):620-5. PubMed ID: 26547265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulmonary presentation of Kawasaki disease-A diagnostic challenge.
    Singh S; Gupta A; Jindal AK; Gupta A; Suri D; Rawat A; Vaidya PC; Singh M
    Pediatr Pulmonol; 2018 Jan; 53(1):103-107. PubMed ID: 28950425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kawasaki disease in infants below 6 months: a clinical conundrum?
    Singh S; Agarwal S; Bhattad S; Gupta A; Suri D; Rawat A; Singhal M; Rohit M
    Int J Rheum Dis; 2016 Sep; 19(9):924-8. PubMed ID: 26990891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effectiveness of infliximab for Kawasaki disease in children: systematic review and meta-analysis.
    Li D; Li X; Dou W; Zheng Y
    Transl Pediatr; 2021 May; 10(5):1294-1306. PubMed ID: 34189087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors of immunoglobulin resistance and coronary complications in children with Kawasaki disease.
    Berdej-Szczot E; Małecka-Tendera E; Gawlik T; Firek-Pędras M; Szydłowski L; Gawlik A
    Kardiol Pol; 2017; 75(3):261-266. PubMed ID: 27995598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous Immunoglobulin Gamma (IVIG) versus IVIG Plus Infliximab in Young Children with Kawasaki Disease.
    Han CL; Zhao SL
    Med Sci Monit; 2018 Oct; 24():7264-7270. PubMed ID: 30307902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?
    Jone PN; Anderson MS; Mulvahill MJ; Heizer H; Glodé MP; Dominguez SR
    Pediatr Infect Dis J; 2018 Oct; 37(10):976-980. PubMed ID: 29461447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrent Kawasaki disease at a tertiary care center in Chandigarh, North West India: 24 years of clinical experience.
    Guleria S; Pilania RK; Jindal AK; Bhattarai D; Suri D; Singh S
    Int J Rheum Dis; 2019 Jul; 22(7):1183-1187. PubMed ID: 30829007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kawasaki disease in children and adolescents: clinical data of Kawasaki patients in a western region (Tyrol) of Austria from 2003-2012.
    Binder E; Griesmaier E; Giner T; Sailer-Höck M; Brunner J
    Pediatr Rheumatol Online J; 2014 Sep; 12(1):37. PubMed ID: 27643389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.